PTX3 and coronary artery disorder: Inflammatory markers such as CRP and PTX3 are involved in both chronic and acute CAD phases highlighting the continuous nature of CAD pathophysiology.[4] Including ACS biomarkers in CAD risk assessment may enhance monitoring for patients at risk of progressing from chronic CAD to acute events.